Rik Parker Writes Overview of Biosimilar Litigation Options for ABA Newsletter

Articles / March 16, 2016

Rik Parker authored an article for Intellectual Property Litigation, a publication of the American Bar Association (ABA) Litigation Section. The article, “Shall We Dance? FDA Biosimilar Approval Process Litigation Options,” examines the provisions of the Biologics Price Competition and Innovation Act (BPCIA) and what litigation options are available to reference product sponsors and to biosimilar applicants under the BPCIA and also beyond it.

Read the article.

Related Services